公开(公告)号：US06780435B2

公开(公告)日：2004-08-24

申请号：US10279622

申请日：2002-10-23

Applicant: Chih-Ming Chen ,  Joseph C. H. Chou ,  Timothy Weng

Inventor： Chih-Ming Chen ,  Joseph C. H. Chou ,  Timothy Weng

IPC: A61K914

CPC classification number: A61K9/5078

Abstract: A pharmaceutical composition of omeprazole for oral administration is described which consists essentially of: (a) a pellet comprising an inert core component, a therapeutically effective amount of omeprazole, a surface active agent, a filler, a pharmaceutically acceptable alkaline agent and a binder; and (b) a single layer of coating on said pellet which comprises a layer of an enteric coating agent.

Abstract translation: 描述了用于口服给药的奥美拉唑的药物组合物，其基本上由以下组成：（a）包含惰性核心组分，治疗有效量的奥美拉唑，表面活性剂，填充剂，药学上可接受的碱性剂和粘合剂的丸剂; 和（b）所述颗粒上的单层涂层，其包含一层肠溶包衣剂。

公开(公告)号：US06720003B2

公开(公告)日：2004-04-13

申请号：US09785040

申请日：2001-02-16

Applicant: Chih-Ming Chen ,  Boyong Li ,  Janice Cacace

Inventor： Chih-Ming Chen ,  Boyong Li ,  Janice Cacace

IPC: A61K920

CPC classification number: A61K31/135 ,  A61K9/146 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/2054 ,  A61K9/2866 ,  A61K31/4525

Abstract: A process for preparing amorphous paroxetine hydrochloride or sertraline hydrochloride is provided, which comprises preparing a solution in which paroxetine hydrochloride or sertraline hydrochloride and a water-soluble polymer are dissolved in a co-solvent of a volatile organic solvent and water. Said solution is dried to obtain a composition comprising amorphous paroxetine hydrochloride or sertraline hydrochloride and the water-soluble matrix.

Abstract translation: 本发明提供了制备无定形帕罗西汀盐酸盐或舍曲林盐酸盐的方法，其包括制备其中将帕罗西汀盐酸盐或舍曲林盐酸盐和水溶性聚合物溶于挥发性有机溶剂和水的共溶剂中的溶液。 将所述溶液干燥以获得包含无定形帕罗西汀盐酸盐或舍曲林盐酸盐和水溶性基质的组合物。

公开(公告)号：US06194249B1

公开(公告)日：2001-02-27

申请号：US09431133

申请日：1999-11-01

Applicant: Ming Hsien Chen ,  Mei-Yen Li ,  Li-Don Chen ,  Chih-Ming Chen

Inventor： Ming Hsien Chen ,  Mei-Yen Li ,  Li-Don Chen ,  Chih-Ming Chen

IPC: H01L2144

CPC classification number: H01L23/3192 ,  H01L23/3142 ,  H01L23/3171 ,  H01L2924/0002 ,  H01L2924/19041 ,  H01L2924/00

Abstract: The invention offers a solution to several problems associated wit IC packages that use a top layer of molded plastic. This has been achieved by inter-posing a dummy layer of dielectric material between the upper surface of the integrated circuit wafer and the molded plastic layer. This dummy layer is patterned and etched so that its surface becomes an alternating series of valleys and ridges, care being taken to ensure that all wiring lines are protected by being within ridges. This structure serves both to protect the wiring lines during the application of the molded plastic and, because of the large surface area of contact between plastic and wafer, excellent adhesion of the molded plastic to the wafer is obtained.

Abstract translation: 本发明提供了与使用顶层模制塑料的IC封装相关的几个问题的解决方案。 这是通过在集成电路晶片的上表面和模制塑料层之间互相构造介电材料的虚设层来实现的。 该虚拟层被图案化和蚀刻，使得其表面变成一系列交替的谷和脊，注意确保所有的布线被脊部保护。 该结构既用于在模塑塑料的应用过程中保护布线，并且由于塑料和晶片之间的大的表面接触面积，所以获得了模塑塑料对晶片的优良粘接性。

公开(公告)号：US06174548B1

公开(公告)日：2001-01-16

申请号：US09143167

申请日：1998-08-28

Applicant: Chih-Ming Chen ,  Joseph Chou ,  Unchalee Kositprapa

Inventor： Chih-Ming Chen ,  Joseph Chou ,  Unchalee Kositprapa

IPC: A61K928

CPC classification number: A61K9/2013 ,  A61K9/2077 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/2886 ,  A61K9/5078 ,  A61K31/4439

Abstract: A pharmaceutical composition of omeprazole for oral administration is described which consists essentially of: (a) a tabletted core component containing a therapeutically effective amount of omeprazole, a surface active agent, a filler, a pharmaceutically acceptable alkaline agent and a binder; and (b) a single layer of coating on said core which comprises a layer of an enteric coating agent.

Abstract translation: 描述了用于口服给药的奥美拉唑的药物组合物，其基本上由以下组成：（a）含有治疗有效量的奥美拉唑，表面活性剂，填充剂，药学上可接受的碱性剂和粘合剂的压片芯组分; 和（b）在所述芯上的单层涂层，其包含一层肠溶包衣剂。

公开(公告)号：US6099862A

公开(公告)日：2000-08-08

申请号：US143876

申请日：1998-08-31

Applicant: Chih-Ming Chen ,  Xiu Xiu Cheng ,  Joseph Chou ,  Steve Jan

Inventor： Chih-Ming Chen ,  Xiu Xiu Cheng ,  Joseph Chou ,  Steve Jan

IPC: A61K9/00 ,  A61K9/20 ,  A61K9/22 ,  A61K9/28 ,  A61K9/36 ,  A61K31/64 ,  A61K9/24

CPC classification number: A61K9/2886 ,  A61K31/64 ,  A61K9/0004 ,  A61K9/2013 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2866

Abstract: A controlled release pharmaceutical tablet containing antihyperglycemic drug and a hypoglycemic drug that does not contain an expanding or gelling polymer layer and comprising a core containing the antihyperglycemic drug and the hypoglycemic drug, a semipermeable coating membrane surrounding the core and at least one passageway in the membrane to allow the drugs to be released from the core.

Abstract translation: 一种含有抗高血糖药物和低血糖药物的控释药物片剂，其不含膨胀或胶凝聚合物层，并且包含含有抗高血糖药物和降血糖药物的核心，围绕芯部的半透性涂膜和膜中的至少一个通道 允许药物从核心释放。

公开(公告)号：US6017828A

公开(公告)日：2000-01-25

申请号：US861172

申请日：1997-05-21

Applicant: Hung-Che Liao ,  Hsien-Wei Chin ,  Chih-Ming Chen

Inventor： Hung-Che Liao ,  Hsien-Wei Chin ,  Chih-Ming Chen

IPC: H01L21/768 ,  H01L21/8244 ,  H01L21/322

CPC classification number: H01L27/11 ,  H01L21/768 ,  Y10S257/903 ,  Y10S257/904 ,  Y10S438/928

Abstract: The present invention is a method for preventing backside polysilicon peeling in 4T+2R SRAM process. This invention utilizes forming oxide cap layer on the backside of the wafer to protect the backside polysilicon. Thus, the backside polysilicon is free from peeling and damage.

Abstract translation: 本发明是防止4T + 2R SRAM工艺中背面多晶硅剥离的方法。 本发明利用晶片背面的形成氧化物盖层来保护背面多晶硅。 因此，背面多晶硅没有剥离和损坏。

公开(公告)号：US5837379A

公开(公告)日：1998-11-17

申请号：US791999

申请日：1997-01-31

Applicant: Chih-Ming Chen ,  Joseph C. H. Chou

Inventor： Chih-Ming Chen ,  Joseph C. H. Chou

IPC: A61K9/00 ,  A61K9/32 ,  A61K9/20

CPC classification number: A61K9/0004

Abstract: A controlled release nifedipine tablet which comprises: (a) a homogeneous compressed core which comprises: (i) a medicament; (ii) a water soluble osmotic compound (iii) one or more osmotic polymers; and (b) a membrane coating which completely covers said core tablet which comprises a mixture of: (i) a water insoluble pharmaceutically acceptable polymer; and (ii) an enteric polymer.

Abstract translation: 一种控释硝苯地平片剂，其包含：（a）均质压缩核心，其包含：（i）药物; （ii）水溶性渗透化合物（iii）一种或多种渗透性聚合物; 和（b）完全覆盖所述芯片的膜包衣，其包含以下混合物：（i）水不溶性药学上可接受的聚合物; 和（ii）肠溶性聚合物。

公开(公告)号：US5736159A

公开(公告)日：1998-04-07

申请号：US430356

申请日：1995-04-28

Applicant: Chih-Ming Chen ,  Der-Yang Lee ,  Jianbo Xie

Inventor： Chih-Ming Chen ,  Der-Yang Lee ,  Jianbo Xie

IPC: A61K9/00 ,  A61K9/28 ,  A61K9/36

CPC classification number: A61K9/0004 ,  A61K9/282 ,  A61K9/2866

Abstract: A controlled release pharmaceutical tablet is disclosed which is based on: (a) a compressed core which contains: (i) a medicament; (ii) at least 23% to 55% by weight, based on the total weight of the core, of a water soluble osmotic agent; (iii) a water soluble pharmaceutically acceptable polymeric binder; (iv) a water-swellable pharmaceutically acceptable polymer; (v) a conventional pharmaceutical excipient; and (b) a membrane coating around said core tablet which consists essentially of: (i) a modified water insoluble pharmaceutically acceptable polymer; and (ii) a pharmaceutically acceptable water soluble polymer.

Abstract translation: 公开了一种控释药物片剂，其基于：（a）压缩核心，其包含：（i）药物; （ii）基于芯的总重量的至少23重量％至55重量％的水溶性渗透剂; （iii）水溶性药学上可接受的聚合物粘合剂; （iv）水溶胀性药学上可接受的聚合物; （v）常规药物赋形剂; 和（b）围绕所述芯片的膜包衣，其基本上由以下组成：（i）改性的水不溶性药学上可接受的聚合物; 和（ii）药学上可接受的水溶性聚合物。

公开(公告)号：US5728402A

公开(公告)日：1998-03-17

申请号：US340290

申请日：1994-11-16

Applicant: Chih-Ming Chen ,  Jane Chang Chen ,  Jainbo Xie ,  Elliot Hahn

Inventor： Chih-Ming Chen ,  Jane Chang Chen ,  Jainbo Xie ,  Elliot Hahn

IPC: A61K9/20 ,  A61K9/28 ,  A61K9/52 ,  A61K31/401 ,  C07D207/16 ,  A61K9/22

CPC classification number: C07D207/16 ,  A61K31/401 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/282

Abstract: The invention provides a controlled release pharmaceutical unit dose composition for oral administration which comprises: (a) an internal phase which comprises captopril or a prodrug of captopril in admixture with a hydrogel forming agent; and (b) an external phase which comprises a coating which resists dissolution in the stomach.

Abstract translation: 本发明提供了用于口服给药的控释药物单位剂量组合物，其包括：（a）内相，其包含与水凝胶形成剂混合的卡托普利或卡托普利前药; 和（b）外部相，其包含抵抗在胃中溶解的涂层。

公开(公告)号：US5472708A

公开(公告)日：1995-12-05

申请号：US290815

申请日：1994-08-16

Applicant: Chih-Ming Chen

Inventor： Chih-Ming Chen

IPC: A61K9/48 ,  A61K9/00 ,  A61K9/20 ,  A61K9/50 ,  A61K9/56

CPC classification number: A61K9/0004 ,  A61K9/2081 ,  A61K9/5084

Abstract: Unit dosage form for delivering drugs into the body in a series of sequential, pulsatile releasing events employs conventional pharmaceutical equipment and processes for optimum economy, reliability, and bioavailability. The system can be used with drugs which cannot be released by diffusion through a porous coating, such as water insoluble drugs. A plurality of populations of pellets is provided within a unit dosage form such as a capsule (8) or tablet. The pellets are composed of a core containing the drug (3) and a swelling agent (4) which expands in volume when exposed to water. The core is enclosed within a membrane or coating which is permeable to water. The membrane is composed of a water insoluble and permeable film forming polymer, a water soluble film forming polymer (11) and a permeability reducing agent (14). When the unit dose releases the pellets into the digestive tract, water diffuses through the coating and into the core. As water is taken up by the swelling agent, the core expands, exerting force on the coating until it bursts, releasing the drug. The permeability reducing agent reduces the rate at which water reaches the swelling agent, thereby delaying release time. The water soluble polymer dissolves, weakening the coating so that it bursts sooner. By varying the proportions of the three coating ingredients and/or coating thickness from one pellet population to another, the release timing of the pellets can be very effectively controlled.

Abstract translation: PCT No.PCT / US93 / 10643 Sec。 371日期：1994年8月16日 102（e）日期1994年8月16日PCT提交1993年11月2日PCT公布。 出版物WO94 / 12160 日期：1994年6月9日。用于以一系列顺序，脉动释放事件将药物输送到体内的单剂剂型采用常规药物设备和方法，以获得最佳的经济性，可靠性和生物利用度。 该系统可以与通过多孔涂层（例如水不溶性药物）扩散而不能释放的药物一起使用。 在单位剂型例如胶囊（8）或片剂中提供多个颗粒群。 颗粒由含有药物（3）的核心和暴露于水时体积膨胀的溶胀剂（4）组成。 核心封闭在可透水的膜或涂层中。 膜由水不溶性且可渗透的成膜聚合物，水溶性成膜聚合物（11）和渗透性还原剂（14）组成。 当单位剂量将丸粒释放到消化道中时，水通过涂层扩散并进入核心。 当水被溶胀剂吸收时，芯膨胀，对涂层施加力，直到爆裂，释放药物。 渗透性降低剂降低水到达溶胀剂的速度，从而延缓释放时间。 水溶性聚合物溶解，削弱涂层，使其更快爆裂。 通过将三种涂层成分的比例和/或涂层厚度从一个粒料群改变到另一个，粒料的释放时间可以被非常有效地控制。